A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies	Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence	Recruiting	Early phase 1	2020-08-21		NCT04283006

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
He Huang	12
Yake Biotechnology Ltd.	30

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Hospital of Zhejiang Medical Colleage Zhejiang University	Hangzhou	China	3

Clinical trials